Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life
Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Correction: Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features
- A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug
- Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single‑cell RNA‑sequencing
- Adenoid cystic carcinoma (ACC)
- DAY301 | Day One Biopharmaceuticals